Posts tagged Biotech Stocks

Diffusion Pharmaceuticals Inc (DFFN): Shoring up the Balance Sheet by Selling Stock Comes with a Price

Shares of clinical-stage biotechnology company Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) are crashing – down nearly 40% as …

Valeant Pharmaceuticals Intl Inc (VRX) Is Taking Reassuring Strides on Back of Strong International Segment

BTIG’s Tim Chiang notes that with various positives soaring in Valeant’s favor, these are mostly reflected in the stock’s recently climbing levels.

Juno Therapeutics Inc (JUNO) Spikes on Rumors of Celgene Takeover; Analysts Dive in

Healthcare analysts share thoughts on a potential acquisition of Juno Therapeutics.

AEterna Zentaris Inc. (USA) (AEZS) Stock Fires Up to the Roof; Here’s Why

AEterna Zentaris Inc. (USA)(NASDAQ:AEZS) investors are busy throwing a party today following the news that tiny …

Oppenheimer Slashes Price Target on Eiger Biopharmaceuticals Inc (EIGR) Following Clinical Failure in PAH, But Remains Bullish

The company’s future is in serious doubt, but it doesn’t prevent Oppenheimer’s Jay Olson from hitting the ‘buy’ button.

Teva Pharmaceutical Industries Ltd (ADR) (TEVA): This Will Not Be the Only Rating Cut to Come

Guggenheim’s Rohit Vanjani reacts to the debt rating downgrade on Teva from the sidelines without shock, having seen the writing on the wall.

Lipocine Inc (LPCN) Stock Is Now a “Show Me” Story

Odds of approval for LPCN’s Tlando come May 8th? H.C. Wainwright’s Oren Livnat says “extremely low,” slicing his price target.

Teva Pharmaceutical Industries Ltd (ADR) Wins Over an Even More Bullish Perspective from Analyst Following Meeting with New CEO

Goldman Sachs’ Jami Rubin now spotlights 16% return potential for TEVA shares, putting his bet on the Israeli pharma giant’s recovery.

Global Blood Therapeutics Inc (GBT): Breakthrough Designation for Lead Asset Has This Top Analyst Hopeful on Voxelotor’s Prospects

One of Wall Street’s best analysts believes “the first cut” of data evaluating GBT’s sickle cell disease drug is looking pretty good right now.

Show More